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CHARGE syndrome is a sporadic autosomal-dominant genetic disorder characterized by a complex array
of birth defects so named for its cardinal features of ocular coloboma, heart defects, choanal atresia,
growth retardation, genital abnormalities, and ear abnormalities. Approximately two-thirds of indivi-
duals clinically diagnosed with CHARGE syndrome have heterozygous loss-of-function mutations in the
gene encoding chromodomain helicase DNA-binding protein 7 (CHD7), an ATP-dependent chromatin
remodeler. To examine the role of Chd7 in development, a zebraﬁsh model was generated through
morpholino (MO)-mediated targeting of the zebraﬁsh chd7 transcript. High doses of chd7 MO induce
lethality early in embryonic development. However, low dose-injected embryos are viable, and by 4 days
post-fertilization, morphant ﬁsh display multiple defects in organ systems analogous to those affected in
humans with CHARGE syndrome. The chd7 morphants show elevated expression of several potent cell-
cycle inhibitors including ink4ab (p16/p15), p21 and p27, accompanied by reduced cell proliferation. We
also show that Chd7 is required for proper organization of neural crest-derived craniofacial cartilage
structures. Strikingly, MO-mediated knockdown of the jumonji domain-containing histone demethylase
fbxl10/kdm2bb, a repressor of ribosomal RNA (rRNA) genes, rescues cell proliferation and cartilage defects
in chd7 morphant embryos and can lead to complete rescue of the CHARGE syndrome phenotype. These
results indicate that CHARGE-like phenotypes in zebraﬁsh can be mitigated through modulation of fbxl10
levels and implicate FBXL10 as a possible therapeutic target in CHARGE syndrome.
& 2013 Elsevier Inc. All rights reserved.Introduction
CHARGE syndrome is an autosomal dominant genetic disorder
that affects 1 in 10,000–18,000 newborns worldwide (Jongmans et al.,
2006; Janssen et al., 2012). CHARGE is an acronym for ocular
coloboma, heart defects, atresia of the choanae, retardation of growth
and development, genital anomalies, and ear malformations/deafness.
The clinical presentation of CHARGE syndrome is highly variable and
may include additional features such as cleft lip/palate, cranial nerve
dysfunction, kidney anomalies, and rare limb anomalies (Zentner et al.,
2010a). Two-thirds of cases of CHARGE syndrome are caused by
spontaneous mutation of the gene encoding chromodomain
helicase DNA binding protein 7 (CHD7), an ATP-dependent chromatinll rights reserved.
and Genome Sciences, 10900remodeler (Vissers et al., 2004; Lalani et al., 2006). Most CHD7
mutations are nonsense, frameshift, or splice-site, predicted to lead
to loss of protein function, and thus CHARGE syndrome is likely due to
reduced dosage of CHD7 (Janssen et al., 2012; Bartels et al., 2010).
Consistent with haploinsufﬁciency as the genetic mechanism under-
lying CHARGE syndrome, mice that are homozygous for Chd7 null
mutations die around embryonic day 10.5, but heterozygous Chd7
mutants are viable and recapitulate many features of CHARGE
syndrome, including heart defects, choanal atresia, postnatal growth
retardation, genital abnormalities, abnormal semicircular canals, and
cleft palate (Bosman et al., 2005; Hurd et al., 2007).
CHD7 is a member of the CHD family of proteins. Nine proteins
comprise this family in vertebrates, and all nine contain tandem
N-terminal chromodomains and a central conserved SNF2-like
ATPase domain presumed to mediate chromatin remodeling.
In addition to the chromodomains and ATPase domain, CHD7
contains two BRK domains of unknown function and a SANT-like
domain that may mediate DNA and/or histone binding (Hall and
S.A. Balow et al. / Developmental Biology 382 (2013) 57–6958Georgel, 2007). CHD7 is a nuclear protein and binds to gene
enhancer elements and promoters, functioning as a transcriptional
co-regulator (Schnetz et al., 2009, 2010; Engelen et al., 2011). CHD7
cooperates with PBAF (polybromo- and BRG1-associated factor-
containing complex) to regulate genes important for formation
and migration of neural crest, including TWIST and SOX9 (Bajpai
et al., 2010). In mouse neural stem cells, CHD7 collaborates with
SOX2 to regulate a common set of target genes including Jag1, Gli3,
and Mycn. Mutations in these and other genes co-regulated by
CHD7 and SOX2 cause clinical malformation syndromes that show
some clinical overlap with CHARGE syndrome (Engelen et al., 2011).
Thus, it is hypothesized that dysregulated expression of genes
normally regulated by CHD7 during development gives rise to the
developmental defects observed in CHARGE syndrome.
In addition to its role as a transcriptional regulator in the
nucleoplasm, CHD7 localizes to the nucleolus (Zentner et al.,
2010b; Kita et al., 2012), where it associates with rDNA and
functions as a positive regulator of rRNA transcription. Cell pro-
liferation is tightly coupled to protein synthesis, ribosome biogen-
esis, and rRNA production (Li et al., 2005; Feng et al., 2010; Pestov
et al., 2001; Holzel et al., 2005). Accordingly, siRNA-mediated
knockdown of CHD7 in cultured cells suppresses protein synthesis
and cell proliferation (Zentner et al., 2010b). Affected tissues from
Chd7mutant mouse embryos also show deﬁciencies in rRNA levels
as well as cell proliferation (Zentner et al., 2010b; Layman et al.,
2011; Hurd et al., 2010). These ﬁndings raise the possibility that
the pathogenesis of CHARGE syndrome is related to that of other
human disorders caused by deﬁciencies in ribosomal biogenesis.
Collectively known as the “ribosomopathies”, these disorders
include Schwachman–Diamond syndrome, dyskeratosis congenita,
cartilage hair hypoplasia, Treacher Collins syndrome, and myelo-
dysplastic syndrome (Narla and Ebert, 2010). Despite these dis-
coveries, it remains unclear if the multiple anomalies in CHARGE
syndrome are due to dysregulated expression of nucleoplasmic
gene targets, rRNA, or the combination of both deﬁcits.
Here, we developed a zebraﬁsh model of CHARGE syndrome
through morpholino-mediated targeting of the zebraﬁsh chd7
homolog. At 4 days post fertilization (dpf) chd7 morphant ﬁsh
show multiple defects in organ systems analogous to those
affected in humans with CHARGE syndrome. The defects in the
chd7morphant ﬁsh are accompanied by a general deﬁciency in cell
proliferation at the early stages of development, associated with
elevated expression of potent cell cycle inhibitors including ink4ab,
p21, and p27. Remarkably, reduction of the Fbxl10/Kdm2bb histone
demethylase, a negative regulator of rRNA transcription, restores
cell proliferation in the chd7 morphants, with concomitant rescue
of CHARGE-like phenotypes. Our ﬁndings implicate cell prolifera-
tion deﬁciencies in the pathogenesis of CHARGE syndrome, and
suggest that elevation of rRNA levels maybe a viable strategy for
therapeutic intervention in CHARGE syndrome.Results
Organization of the zebraﬁsh chd7 gene
The sole zebraﬁsh chd7 gene is located on chromosome 2 (Zv9
Ensembl). Of the ﬁve annotated transcripts, one is non-protein
coding, two contain only the ﬁrst two or three exons, and the
remaining two are full-length. Both of the full-length transcripts have
identical predicted protein coding sequences and have an exon–
intron structure similar to that of human CHD7. These full-length
transcripts code for a zebraﬁsh Chd7 protein of 3140 amino acids,
which is slightly longer than the human homolog of 2997 amino
acids. Additionally, the zebraﬁsh Chd7 protein contains a similar
complement of protein domains including tandem N-terminalchromodomains, a central SNF2-like ATPase/helicase domain, and a
C-terminal BRK domain (Fig. 1A). The N-termini of zChd7 and hCHD7
are less conserved; however, the remainder of Chd7, including all of
the functional domains, is highly similar. Overall, the aligning portion
of the zChd7 sequence demonstrates 69% identity to hCHD7 at the
amino acid level.chd7-morpholino gene targeting recapitulates major features of
CHARGE syndrome
To model CHD7 haploinsufﬁciency in zebraﬁsh, an antisense
morpholino (MO) was designed to produce a mis-spliced chd7
transcript containing a premature stop codon. Speciﬁcally, the MO
was targeted to the junction of chd7 intron 15 and exon 16 to induce
production of a transcript either missing exon 16 or one including
intron 15 (Fig. 1B, upper). We performed RT-PCR analysis using
multiple combinations of primers designed to amplify transcripts
containing exon 15 mis-spliced to exon 17. However, such transcripts
were not detected in chd7 MO-injected embryo, raising the possibility
that the chd7MO blocks splicing of exons 15 and 16, leading to intron
inclusion. We therefore performed RT-PCR analysis using multiple
primer sets designed to amplify transcript containing an intron 15
inclusion. The expected wild-type transcript was ampliﬁed with cDNA
from control embryos. The wild-type transcript was also present in
chd7 morphant embryos, even upon treatment with high doses of
chd7 MO. However, chd7 morphant embryos also expressed a larger
transcript, consistent with intron inclusion (Fig. 1C). The levels of the
chd7 morphant transcript increased in an MO dose-dependent man-
ner (Fig. 1D). Direct sequence analysis of the morphant transcript
cDNA revealed inclusion of intron 15. In silico translation of the
morphant transcript predicts mis-incorporation of a premature stop
codon at 1383 amino acids past the ﬁrst codon (Fig. 1B, lower),
presumably leading to degradation of the morphant chd7message via
nonsense-mediated decay.
The chd7 morphants exhibited CHARGE-like defects in an MO
dose-dependent manner. Speciﬁcally, high doses of chd7-MO
(5–10 ng) induced lethality within 24 h post-fertilization (hpf),
reminiscent of embryonic lethality observed in homozygous null
Chd7 mice (Bosman et al., 2005; Hurd et al., 2007). Low-doses
of chd7-MO (2.5 ng) yielded viable ﬁsh that were indistinguishable
from wild-type and control-injected embryos at 3 days post-
fertilization (dpf). However, multiple defects were apparent at
4 dpf (Fig. 2A–D). Approximately 95% of low-dose chd7-MO
injected embryos showed an abnormal phenotype (Fig. 2E–L). chd7
morphant ﬁsh developed defects in organs analogous to those
affected in humans and mice with heterozygous CHD7 mutations
(Supplemental Table 1). Defects included pectoral ﬁn hypoplasia
(60%), eye abnormalities (70%), and abnormalities in both otolith
morphology and number (approximately 25% and 10% respectively)
(Fig. 2E–L). Moreover, 60% of chd7 morphants presented with heart
defects including pericardial edema, weak heartbeat with reduced
circulatory ﬂow, and occasionally a lack of proper heart tube folding.
Importantly, 64% of chd7morphants also exhibited craniofacial defects
involving the nasal region and jaw (Fig. 3A–B). None of these defects
were apparent upon injection of a chd7 MO containing a 5-bp
mismatch to the endogenous chd7 gene, indicating that the observed
defects are speciﬁc to chd7 targeting. To further verify speciﬁcity, we
tested a second splice-blocker chd7MO, and a third chd7-MO designed
to block translation. Both the second splice-blocker and chd7-transla-
tion blocker yielded similar phenotypes to that seen with the original
splice blocker MO, although the translation blocker yielded more
severe heart defects, and ear defects were observed at a higher
frequency. No aspects of chd7 morphant phenotype were rescued
upon co-injection of chd7 and p53 morpholinos, indicating that the
observed defects in the chd7 morphants are unlikely to be related to
Fig. 1. Morpholino targeting of the zebraﬁsh chd7 RNA induces an aberrant transcript. (A) Schematic of the human CHD7 and zebraﬁsh Chd7 proteins with the location of the
predicted protein domains. (B) Schematic of the zebraﬁsh un-spliced chd7 transcript (upper) and the exon/intron splice site targeted by the chd7 morpholino (black bar).
Schematic of the chd7 morphant transcript (lower) with the location of the predicted induced nonsense mutation (black arrow). Chromatogram of the sequenced morphant
transcript PCR product reveals a nonsense mutation (red highlight). (C) Agarose gel with the ampliﬁed PCR products of both wild-type and morphant chd7 transcripts from
Std control morphants and chd7morphants. (D) Graph of qRT-PCR data quantifying the expression of the chd7morphant transcript. Error bars represent standard error of the
mean (SEM) (n¼4). Signiﬁcance was determined by a Student's two-tailed t-test and signiﬁcant p-values are noted po0.01 (**). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
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observed phenotype resembles that reported in a separate study in
which the chd7 gene was targeted using a different splice-blocker MO
(Jacobs-McDaniels and Albertson, 2011; Patten et al., 2012). Overall,
the chd7 morphants displayed defects in many of the same organs
affected in humans and mice with CHD7 mutations, including the ear,
eye, heart, craniofacial region, and limbs. Thus, the requirement for
CHD7 in the development of these organs appears to be conserved
between mice, humans, and zebraﬁsh, and suggests that MO-
mediated targeting of chd7 creates a suitable system to examine
Chd7 function in development.chd7 morphants develop defects in neural crest-derived craniofacial
cartilage
Early zebraﬁsh craniofacial structure is dependent on proper
migration of the multipotent cranial neural cells from the neural tube
into the pharyngeal arches. These cells differentiate to form several
tissues of the developing cranium such as the cranial nerves, bones,
and cartilage (Knight and Schilling, 2006). Based on these ﬁndings and
published studies implicating a deﬁciency in neural crest cell migra-
tion in CHARGE syndrome (Bajpai et al., 2010; Patten et al., 2012), we
performed a detailed morphological analysis of craniofacial cartilage in
Fig. 2. Zebraﬁsh chd7 targeting results in CHARGE-like phenotypes. Whole-embryo lateral (A, C) and dorsal (B, D) views of representative Std control and chd7 morphant
embryos at 4 dpf. The chd7 morphants display pectoral ﬁn defects (E–F), eye abnormalities including under-developed or missing anterior eye structures (G–H), changes in
otolith morphology (I–J), and pericardial edema (K–L). Missing or abnormal structures are highlighted with an asterisk (n) and/or dashed line. Structures are also highlighted
in Std morphants for comparison. HT¼heart, L¼ lens, OT¼otolith, PE¼pericardial edema, PEC¼pectoral ﬁn, and R¼retina.
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injected controls, chd7morphants showed a wide range of craniofacial
cartilage abnormalities (Fig. 3F–G). In approximately 50% of chd7
morphants, the ﬁrst pharyngeal arch comprising Meckel's cartilage
and the palatoquadrate were morphologically normal. However,
Meckel's cartilage was located posteriorly to that observed in control
morphants. In addition, the ceratobranchial cartilages were absent,
and the ceratohyal was malformed (less V-shaped) compared to
controls. In the majority of chd7morphants, the ceratobranchial arches
were undetectable at this resolution. However, microscopic analysis of
sagittal sections revealed that the ﬁrst ceratobranchial arch was
occasionally present (Supplemental Fig. 1). In more severely affected
chd7morphants, the only craniofacial cartilage structure observed was
a severely underdeveloped neurocranium with malformed parachor-
dal and trabecula cranii cartilages. Interestingly, parachordal and
trabecula cranii cartilages are partially derived from mesoderm, while
the more anterior cartilage structures that were typically absent in the
severe chd7 morphants are mostly derived from neural crest (Kague
et al., 2012). These results suggest that chd7 plays a critical role in the
formation of cranial neural crest-derived cartilage tissues.
Chd7 is required for normal cellular proliferation during zebraﬁsh
development
In E9.5–E10.5 mouse embryos, haploinsufﬁciency of CHD7 is
associated with reduced proliferation of olfactory neural stem cellsand cells of the otic epithelium and ganglion (Layman et al., 2011;
Hurd et al., 2010). Moreover, we previously showed that siRNA-
mediated knockdown of CHD7 in cultured cells attenuates their
proliferation (Zentner et al., 2010b). These proliferative deﬁcien-
cies occur without concomitant increases in cell death, indicating
that CHD7 regulates cell proliferation and not apoptosis. We tested
for proliferative defects in the chd7 morphants through immuno-
ﬂuorescence analysis of phosphorylated histone H3 at serine 10
(P-H3), a marker of mitosis (Fig. 4A–B). Compared to control
embryos, the total area positive for cellular P-H3 expression in
chd7 morphants (25 hpf) was reduced by 37% in the anterior
region of the embryo (Fig. 4C). In addition, counts of P-H3
immuno-positive cells showed a 47% reduction in the total
number of proliferating cells in chd7 morphants compared to
controls (Fig. 4D–E). A reduction in the number of proliferating
cells was detected not only in the anterior region of the embryo
(Fig. 4D), where chd7 levels are high at this stage of development,
but also the tail region (Fig. 4E), where chd7 levels are low.
Zebraﬁsh chd7 expression is ubiquitous in early development
and becomes more anteriorized around 3 dpf (Rauch et al.,
2003). Thus, the observed proliferative deﬁciencies are probably
related to Chd7's role during early development, prior to the time
at which chd7 expression is restricted to the anterior region of the
zebraﬁsh embryo.
Similar to the ﬁndings in mice and cultured cells, the prolif-
erative defects in the chd7 morphants occurred in the absence of
Fig. 3. chd7morphants display variable defects in craniofacial cartilage development. (A–B) Bright-ﬁeld lateral views of representative Std control morphants and chd7morphants at
4 dpf. (C–D) Lateral and ventral views of Std morphants with wild-type craniofacial cartilage structures at 4 dpf. (F–G) Representative lateral and ventral views of the average chd7
morphant phenotype and is categorized as underdeveloped. The ceratohyal cartilages of the chd7 morphant are malformed and form a more linear shape. The ﬁve ceratobranchial
cartilages were also undetectable with Alcian blue staining. (I–J) Lateral and ventral views of a severe chd7morphant phenotype detected a highly underdeveloped neurocraniumwith
the anterior and branchial arches absent. (E, H, K) Schematic views of the zebraﬁsh craniofacial cartilage excluding the neurocranium. A solid red line indicates that the structure is
present but malformed; while, a dashed red line indicates that the structure is absent. AC¼auditory capsule, CB¼ceratobranchial, CH¼ceratohyal, EP¼ethmoid plate, ME¼Meckel's
cartilage, N¼notochord, PC¼parachordal, PEC¼pectoral ﬁn, PQ¼palatoquadrate, and T¼trabeculacranii. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
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The proliferative deﬁciencies were accompanied by elevated
expression of potent cell-cycle inhibitors, including p21, p27, and
ink4ab (the zebraﬁsh homolog of both p15 and p16) (Sabaawy
et al., 2006) (Fig. 4F–H). Because we have previously shown that
decreases in rRNA correlate with reduced proliferation, we also
quantiﬁed the levels of 45S pre-rRNA, the product of Pol I
transcription of rDNA that is ultimately processed into the mature
18S, 5S, and 28S ribosomal subunits (Zentner et al., 2010b; McStay
and Grummt, 2008). No signiﬁcant differences in pre-rRNA levels
were detected between chd7 morphants and controls, even in
embryos injected with high doses of chd7MO (Fig. 4I). Thus, either
Chd7 does not regulate rRNA in the zebraﬁsh, or the effect is
restricted to speciﬁc cell types or other stages of development.
Overall, these ﬁndings indicate that Chd7 is required for normal
cellular proliferation in the developing zebraﬁsh embryo, although
it is currently not clear from these data that the effect is mediated
through rDNA regulation.Fig. 4. chd7 targeting impairs cell proliferation. (A–B) Lateral views of representative P-H
P-H3 positive cells in chd7morphants relative to P-H3 positive cells in Std morphants (n¼
the head and tail regions of Std and chd7morphants (n¼4–6). (F–H) Graphs of qRT-PCR d
morphants relative to Std morphants (n¼5–6). (I) Expression of pre-rRNA in chd7morph
All error bars represent SEM. Signiﬁcance for all graphs was determined with a StudentFbxl10 regulates rRNA levels during zebraﬁsh embryogenesis
Cell proliferation rates are tightly coupled to ribosomal RNA
levels. Though our results were inconclusive as to whether zebraﬁsh
Chd7 regulates rRNA, we set out to modulate rRNA levels in chd7
morphants, reasoning that this might restore the proliferative
deﬁciencies. To achieve this, we chose to knockdown the homolog
of a known repressor of rRNA genes in mammals: FBXL10 (also
known as NDY1, JHDM1B, and KDM2B). FBXL10 is a jumonji
domain-containing histone demethylase that represses rRNA genes
in the mammalian nucleolus, suppressing cell proliferation (Frescas
et al., 2007). Other studies contradict these ﬁndings, suggesting that
FBXL10 increases proliferation by directly suppressing cell-cycle
inhibitors in the nucleoplasm, including p15Ink4b, p16Ink4a, and
p19Arf (He et al., 2008; Tzatsos et al., 2009, 2011). Similarly to chd7,
fbxl10 (kdm2bb) is expressed ubiquitously throughout early zebra-
ﬁsh embryogenesis. By 4 dpf, fbxl10 expression is restricted to the
anterior embryo including the retina and central nervous system3 stained zebraﬁsh morphants at 25 hpf. (C) Quantiﬁcation of the area occupied by
5–6). (D–E) Graphs of P-H3 positive cell counts taken from confocal images of both
ata measuring gene expression of several cell cycle regulator genes at 25 hpf in chd7
ants at two separate morpholino dosages relative to Std morphants at 8 hpf (n¼3).
's two-tailed t-test and signiﬁcant values are noted po0.01 (**) and po0.001 (***).
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knocked down fbxl10 transcript levels by 35% to 50% (Fig. 5A–B).
When 5 ng of MO was injected, the fbxl10 knockdown yielded
viable ﬁsh without an obvious gross morphological abnormalities or
defects in craniofacial cartilage structures (Fig. 5C–D, Supplemental
Fig. 2). Additionally, fbxl10 knockdown did not impact cell prolif-
eration (Fig. 5E–G). However, higher doses of fbxl10 morpholino
induced early embryonic lethality by 24 hpf. Also, chd7 expression
was also found to be normal in fbxl10 morphants when measured
by qRT-PCR (not shown). We next tested if Fbxl10 regulates rRNA in
the nucleolus or cell cycle genes in the nucleoplasm. 45S pre-rRNA
levels were 30% higher in embryos injected with fbxl10-MO than
control embryos (Fig. 5H). ink4ab levels were not signiﬁcantly
different between controls and fbxl10 morphants (Fig. 5I). TheseFig. 5. Targeting of zebraﬁsh fbxl10 transcript modulates pre-rRNA expression. (A) Sche
(black bar). Injection of the morpholino results in an exclusion of exon 2 in the matur
Exclusion of exon 2 in the fbxl10 morphant transcript was conﬁrmed by PCR. (B) Gra
expression in Std control morphants at 8 hpf (n¼4). (C–D) Representative lateral (C
representative P-H3 stained zebraﬁsh morphants at 25 hpf. (G) Quantiﬁcation of the area
Std morphants (n¼12–13). (H) Graph of qRT-PCR expression data for 45S pre-rRNA relat
measuring ink4ab expression relative to Std morphants (n¼6).Error bars in all graphs rep
values are noted po0.05 (*) and po0.01 (**).results support the reported mammalian function of Fbxl10 as a
repressor of rRNA genes in the nucleolus.Rescue of chd7 morphant phenotype upon knockdown of fbxl10
Having established that Fbxl10 represses rRNA levels in the ﬁsh,
we tested the effects of knocking down both fbxl10 and chd7, through
co-injection of chd7 and fbxl10 morpholinos. Co-injection of fbxl10-
MO and the chd7-translation blocker MO induced embryonic leth-
ality within 24 hpf. However, co-injection of fbxl10-MO with the chd7
splice blocker MO suppressed the morphological defects induced by
chd7 morpholino alone. Speciﬁcally, co-injection of chd7 and fbxl10
morpholinos reduced the penetrance of pericardial edema (13% frommatic of the un-spliced fbxl10 transcript and the location of the fbxl10 morpholino
e fbxl10 transcript and is predicted to induce a nonsense mutation (black arrow).
ph of qRT-PCR data measuring the expression of wild-type fbxl10 relative to the
) and dorsal (D) bright-ﬁeld images of fbxl10 morphants.(E–F) Lateral views of
occupied by P-H3 positive cells in fbxl10morphants relative to P-H3 positive cells in
ive in fbxl10 morphants relative to Std morphants (n¼4). (I) Graph of qRT-PCR data
resent SEM. Signiﬁcance determined by a Student's two-tailed t-test and signiﬁcant
S.A. Balow et al. / Developmental Biology 382 (2013) 57–696458%), eye abnormalities (11% from 73%), pectoral ﬁn defects (8% from
55%), craniofacial defects (27% from 64%), and otolith abnormalities
(0% from 25%) (Fig. 6A). In addition to the improvement of
gross morphology discussed above, we also observed a signiﬁcantFig. 6. Modulation of fbxl10 expression rescues CHARGE-like phenotypes and improves
phenotypes across the different zebraﬁsh morphants. Signiﬁcance was determined by ch
the chd7/fbxl10 double morphants compared to controls (B) at 4 dpf including morphant
fbxl10 double morphants with severe ceratohyal malformations and ceratobranchial cart
cartilage phenotypes in the developing zebraﬁsh. Zebraﬁsh were categorized on the sev
present but displayed morphological changes in the ceratohyal. “Underdeveloped” m
ceratohyal. A morphant was categorized “Absent” with no detectable anterior and branch
(G–H) Lateral views of representative P-H3 stained zebraﬁsh Std and chd7/fbxl10 morph
morphants (re-plotted from Fig. 4C) and chd7/fbxl10 morphants relative to P-H3 posit
products of both wild-type and morphant chd7 transcripts from 8 hpf across the panel
po0.001 (***). AC¼auditory capsule, CB¼ceratobranchial, CH¼ceratohyal, EP¼ethmoirestoration in overall head size in the chd7/fbxl10 double morphants
compared to the chd7 morphant (Supplemental Fig. 3).
Forty-six percent of co-injected morphants showed restoration of
the craniofacial cartilage to wild-type or near wild-type morphologycellular proliferation defects. (A) Graph of the percentage of observed CHARGE-like
i-square tests. (B–E) Lateral and ventral views of representative cartilage staining in
s with normal phenotypes (C), mild malformations of the ceratohyal (D), and chd7/
ilage were undetectable (E). (F) Graph of the frequency of the observed craniofacial
erity of the craniofacial cartilage defect. “Malformed” morphants had all cartilages
orphants had no detectable ceratobranchial arches in addition to a malformed
ial arches. A highly underdeveloped neurocraniumwas present in these morphants.
ants at 25 hpf. (I) Quantiﬁcation of the area occupied by P-H3 positive cells in chd7
ive cells in Std morphants (n¼7). (J) Representative image of the ampliﬁed PCR
of morphants. Signiﬁcant p-values in all graphs are noted po0.05 (*), po0.01 (**),
d plate, ME¼Meckel's cartilage, and PQ¼palatoquadrate.
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(Fig. 6B–C, Supplemental Fig. 4A). Compared to the single chd7
morphants (Fig. 3F–G), the chd7/fbxl10morphants had more anteriorly
developed Meckel's cartilage, a wild-type or near wild-type ceratohyal
morphology, and all ceratobranchial arches were detectable upon
Alcian blue staining. The remaining 54% showed craniofacial cartilage
abnormalities similar to those observed in chd7 single morphants, but
in general, these abnormalities were less severe than those seen in the
single chd7morphants (Fig. 6D–F). For example, the chd7/fbxl10 double
morphants had a similar proportion of morphants categorized to be
malformed compared to the chd7 single morphants due to more linear
ceratohyal morphologies (Fig. 6D, Supplemental Fig. 4B). However,
only a small proportion of the chd7/fbxl10 double morphants were
scored as underdeveloped with both an inverted ceratohyal cartilage
and undetectable ceratobranchial arches (Fig. 6E, Supplemental
Fig. 4C). This indicates a signiﬁcant restoration of the ceratobranchial
arches in the double morphants. The craniofacial cartilage structures in
the majority of single fbxl10morphants injected in parallel were again
indistinguishable from the standard-MO controls (Fig. 6F).
We also analyzed cell proliferation through quantitative analy-
sis of P-H3 immuno-positive cells in morphant embryos. RelativeFig. 7. Gene expression changes in cell-cycle regulators in chd7/fbxl10 double morphan
morphants (re-plotted for comparison from Fig. 5H) relative to Std morphants at 8 hpf (n
regulator genes at 25 hpf across the panel of morphant embryos relative to Std morphan
comparison. Error bars represent SEM. Signiﬁcance for all graphs was determined with a
po0.001 (***).to controls, the percentage of mitotic cells within measured areas
increased from 63% in chd7 single morphants to 78% in co-injected
embryos (Fig. 6G–I). Importantly, these percentages reﬂect average
counts from multiple co-injected embryos, from which the degree
of rescue was variable. In fact, analysis of individual P-H3 immu-
nostained embryos showed complete to near-complete restoration
of cell proliferation in approximately two-thirds of all embryos
analyzed (n¼29). Overall, these data indicate that knockdown of
fbxl10 can mitigate chd7-morphant phenotypes in zebraﬁsh.
Importantly, co-injected embryos retained the chd7 morphant
transcript, indicating that the effects of Fbxl10 depletion genuinely
trump those of Chd7 depletion, and that rescue is not simply due
to loss of the chd7 morphant transcript (Fig. 6J).
Analysis of rRNA and cell cycle genes in fbxl10/chd7 double
morphants
To gain insights into the mechanism underlying the fbxl10-
mediated rescue, we compared the levels of rRNA, p21, p27, and
ink4ab in fbxl10/chd7 co-injected morphant embryos to those in
chd7 single morphants and standard-injected embryos. Thesets. (A) Expression of pre-rRNA in chd7/fbxl10 double morphants and fbxl10 single
¼3). (B–D) Graphs of qRT-PCR data measuring gene expression of several cell cycle
ts (n¼5–6). Expression data for chd7 morphants re-plotted here from Fig. 4F–H for
Student's two-tailed t-test and signiﬁcant values are noted po0.05 (*), po0.01 (**),
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First, 46% of co-injected embryos show rescue by 4 dpf, and, at the
25 hpf time point at which embryos are collected to perform the
assay, one cannot distinguish rescued embryos from those that
will fail to show rescue. In addition, embryos must be pooled to
obtain sufﬁcient quantities of RNA for the analysis. Nonetheless,
we found that pre-rRNA levels were similar between co-injected
and control-injected embryos, indicating that the fbxl10-mediated
increases in rRNA are attenuated through targeted knockdown of
chd7 (Fig. 7A). Thus, even though reduced rRNA levels were not
detected in the chd7 single morphants, elevated rRNA levels in the
fbxl10 morphants are clearly attenuated upon knockdown of chd7,
suggesting that Chd7's role as a positive regulator of rRNA may be
context speciﬁc. p27 levels, elevated in the chd7 single morphants,
were also attenuated upon co-injection of fbxl10 and chd7 mor-
pholinos (Fig. 7B). p21 and ink4ab levels in chd7 single morphants
were not signiﬁcantly different from co-injected embryos (Fig. 7C–
D). However, these results reﬂect transcript levels measured from
pooled co-injected embryos, of which 46% were rescued and 54%
remained morphant. Thus, the levels of p21 and ink4ab shown in
the plots, which are clearly trending downward, may be much
lower in the 46% of embryos that were rescued. Based on these
ﬁndings, we propose that elevated rRNA levels, induced upon
knockdown of fbxl10, leads to suppression of cell cycle inhibitors
activated upon chd7 targeting, thereby alleviating the chd7-asso-
ciated cell proliferation defect.Discussion
To study the role of Chd7 during development, we generated a
zebraﬁsh model of CHARGE syndrome through MO-mediated gene
targeting. The chd7 morphant phenotype is highly MO dose-
dependent, with high doses leading to early embryonic lethality
and lower doses yielding viable ﬁsh with craniofacial defects as
well as malformations of the eye, heart, otoliths, and pectoral ﬁns.
The chd7 morphants also show cranial cartilage abnormalities,
consistent with a defect in developing neural crest, the proposed
cell type of origin for many of the anomalies observed in CHARGE
syndrome patients (Bajpai et al., 2010; Patten et al., 2012; Siebert
et al., 1985; Sanlaville et al., 2006; Randall et al., 2009). The chd7
morphant embryos also display widespread deﬁciencies in cellular
proliferation, accompanied by elevated levels of potent cell-cycle
inhibitors. Remarkably, the gross morphological alterations, carti-
lage abnormalities, and cell proliferation deﬁciencies that deﬁne
the chd7 morphant phenotype are all restorable with knockdown
of Fbxl10, a repressor of rRNA. We propose that the mechanism of
rescue is due to suppression of cell cycle inhibitors that are
activated upon chd7 targeting, possibly through global modulation
of rRNA levels.
To date, zebraﬁsh, frogs, and mice have been used to study the
role of CHD7 in development (Bosman et al., 2005; Hurd et al.,
2007; Bajpai et al., 2010; Patten et al., 2012; Layman et al., 2009;
Tian et al., 2012). The overall phenotype and the organ systems
affected in the chd7 morphants reported here are consistent with
those previously observed in the other models (Supplemental
Table 1). For example, defects in neural crest development and
malformed craniofacial cartilage structures were previously
reported in both zebraﬁsh and frogs. Similarly to our zebraﬁsh
model, the frog model also shows facial width compression (Bajpai
et al., 2010). As in the previously described zebraﬁsh, frog, and
mouse models, chd7 morphants described here show eye, heart,
and otolith abnormalities. However the speciﬁc anomalies
described vary somewhat between the models. With respect to
the eyes for example, our zebraﬁsh models show an underdeve-
loped lens, the previously described zebraﬁsh models show retinaldisorganization, the frog models develop colobomas, and the
mouse models present with keratoconjunctivitis sicca (Bosman
et al., 2005; Bajpai et al., 2010; Patten et al., 2012; Tian et al., 2012).
The underlying basis for these differences is not known, but
interestingly, this phenotypic variability is highly reminiscent of
that seen among human patients with CHARGE syndrome and
warrants further study.
To better understand the contribution of the proliferative deﬁcien-
cies to the overall phenotype of the chd7 morphants, we knocked
down the levels of fbxl10/kdm2bb, a histone demethylase that nor-
mally suppresses cell proliferation and has a similar spatiotemporal
expression pattern to chd7 (Rauch et al., 2003; Frescas et al., 2007; He
et al., 2008; Tzatsos et al., 2009; Thisse and Thisse, 2004). To our
knowledge, this is the ﬁrst report of a zebraﬁsh fbxl10 morphant
model, and the ﬁrst report that fbxl10 modulates rRNA levels in the
zebraﬁsh. Fifty percent reduction of fbxl10 did not yield any gross
morphological abnormalities. However, more substantial decreases of
fbxl10 induced early embryonic lethality by the end of the segmenta-
tion period (24 hpf). This phenotype is somewhat reminiscent of that
observed in Fbxl10 mutant mice. Speciﬁcally, fbxl10 heterozygotes
develop normally, while fbxl10-null homozygotes die during late
embryogenesis or shortly after birth (Fukuda et al., 2011).
It has been demonstrated in several model systems that decrease
in CHD7 levels impair cellular proliferation in multiple cell types
(Zentner et al., 2010b; Layman et al., 2011). Our studies not only
corroborate these ﬁndings, but also implicate proliferative deﬁciencies
as the basis for the developmental anomalies observed in the zebraﬁsh
model of CHARGE syndrome. The rescue of a multiple congenital
anomaly syndrome caused by a deﬁciency in rRNA biogenesis is not
unprecedented. Treacher-Collins Syndrome (TCS) is a congenital dis-
order of craniofacial development caused by mutations in TCOF1 and
POLR1D (Edwards et al., 1997; Gladwin et al., 1996; Dauwerse et al.,
2011). These mutations lead to reduced rRNA biogenesis, and similarly
to CHARGE syndrome, neural crest is implicated as the cell type of
origin for most of the associated anomalies in TCS. In mouse models of
TCS, impaired ribosome biogenesis triggers the nucleolar stress
response, activating p53 and leading to proliferative deﬁciencies and
apoptosis of neural crest cells. Moreover, inhibition of p53 blocks
neural crest apoptosis and rescues the craniofacial defects (Jones et al.,
2008). In our study, several genes associated with the nucleolar stress
response, including p21, p27 and rRNA itself, responded upon MO-
targeting of chd7 and fbxl10. These ﬁndings lead us to hypothesize that
the cell proliferation defects observed in the chd7 morphants are due
to activation of the nucleolar stress response, like in TCS. However,
MO-mediated knockdown of p53 failed to rescue the chd7 morphant
phenotype. Additionally, we previously showed that proliferative
deﬁciencies induced upon knockdown of CHD7 in cultured cells were
accompanied by changes in the levels of rRNA and p21, but not p53
(Zentner et al., 2010b). Thus, if the nucleolar stress response is the
basis of the proliferative defect seen in the chd7 morphants, and the
mechanism of rescue is due to suppression of the nucleolar stress
response, it is likely to be p53-independent.
Together with the proposed role for CHD7 as a regulator of
rRNA transcription in the nucleolus, the multiple anomalies in
CHARGE syndrome are thought to due to insufﬁciencies in cell
speciﬁcation and proliferation during development. Our ﬁndings
in the zebraﬁsh suggest that restoring the cell proliferative
deﬁciencies at the early stages of embryogenesis, even in the
context of the other cellular deﬁcits, could be sufﬁcient to
attenuate or altogether bypass the developmental defects asso-
ciated with CHD7 mutation. Our studies lay the foundation to test
this hypothesis in higher vertebrates, either through targeted
modulation of FBXL10 or other genes that regulate rRNA levels,
or genes that directly regulate the cell cycle. It is also noteworthy
that histone demethylases are particularly amenable to targeting
with small-molecule inhibitors (Cole, 2008; Lohse et al., 2011).
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we might be able to tap into this growing area of therapeutic
research for application to CHARGE syndrome.Methods
Zebraﬁsh maintenance
Wild-type Tuebingen (TÜ) zebraﬁsh (Danio rerio) embryos were
raised at 28 1C. The zebraﬁsh were raised on 14-hour light cycle
and 10-hour dark cycle.
Protein sequence comparison
Human CHD7 (NP_060250.2) and zebraﬁsh Chd7 (ENSDART
00000016208) protein sequences were aligned using the NCBI BLAST
blastp suite to determine the degree of amino acid overlap between
the two sequences (Altschul et al., 1997). To retrieve the predicted
domain composition of each protein sequence, we used the NCBI
Conserved Domain Database (Marchler-Bauer et al., 2011).
Morpholino design and injection
A splice-blocking morpholino, 5′-ACCTACAATGAAGGAAATAGG-
CCGT-3′, a 5-bp mismatch control morpholino, 5′-ACGTAGAATCAG-
CAAATACGCCGT-3′, a second conﬁrmation splice-blocking morpho-
lino, 5′-TGTGCCTGGAGGCAACAGCACAAAC-3′, and a translation-
blocking morpholino, 5′-GGCTCATCATGCCTGGGTCAGCCAT-3′ were
designed against the zebraﬁsh chd7 transcript (ENSDART000000
16208). To reduce fbxl10 expression, we used a splice-blocking
morpholino designed against the zebraﬁsh fbxl10 transcript (ENSDART
00000102530), 5′-ACAACACCTGAGAACAGAAGCAGGA-3. To target
p53 expression, we used a previously characterized morpholino
(Langheinrich et al., 2002). To control for phenotypes resulting from
the injection procedure alone, a standard control morpholino that has
no target or biological activity within the zebraﬁsh was used in all
experiments (Gene Tools). Phenotypes between standard morphants
and those injected with the 5-bp mismatch chd7 morpholino were
comparable. Zebraﬁsh embryos received 2.5 ng of chd7 morpholino,
5 ng of standard control morpholino, 4 ng p53 morpholino, or 5 ng
fbxl10 morpholino unless concentration is indicated otherwise. The
chd7/fbxl10 double morphants received a simultaneous injection of
2.5 ng chd7 morpholino and 5 ng fbxl10 morpholino. The chd7/p53
double morphants received a simultaneous injection of 2.5 ng chd7
morpholino and 4 ng p53 morpholino. This p53 morpholino dosage
was slightly higher than that recommended for testing for non-
speciﬁc morpholino related cell death (Robu et al., 2007). For all co-
injection experiments, chd7 and fbxl10 or chd7 and p53 morpholino
single injections were performed in parallel as an additional control.
All morpholinos were designed and manufactured by Gene Tools
(Philomath, Oregon). Morpholinos were dissolved in sterile water to
stock solution of 65 mg/ml. 5 mg/ml or 10 mg/ml working solutions
were made by diluting the morpholino in water and 2% phenyl red.
Zebraﬁsh embryos were then injected at the 1 or 2 cell stage with
using a microinjector.
Scoring of zebraﬁsh morphant phenotypes
Zebraﬁsh embryos were incubated at 28 1C in ﬁsh water until the
desired developmental stage was reached. The chd7 morphant phe-
notypes were monitored and scored using a Leica S6E stereomicro-
scope between 4 and 6 dpf. The bright-ﬁeld images of chd7morphant
phenotypes were taken at 6 dpf and were images on a Leica DM6000.
Signiﬁcance was assessed by chi-square contingency test.RNA extraction, cDNA synthesis, and qRT-PCR
Total RNA was extracted by homogenizing 20–30 pooled
embryos at 8 hpf or 25 hpf in Trizol reagent (Invitrogen). Embryos
were homogenized by drawing them through a 21G 1½ needle and
1 ml syringe (BD) approximately 20 times. RNA was further
puriﬁed via the Trizol Reagent protocol (Invitrogen) and was re-
dissolved in RNase-free water. From the total puriﬁed RNA, cDNA
was synthesized using a High-capacity cDNA Archive Kit (Applied
Biosystems). Using quantitative polymerase-chain reaction (PCR),
gene expression was measured in triplicates across a set of three
biological replicates. PCR reactions were performed using Sybr-
Green or Taqman chemistry on an ABI 7300 real-time thermo-
cycler. Designed primer sequences for PCR reactions are listed in
Table 2. Expression of the 45S rRNA transcript measured using a
previously published primer set (Azuma et al., 2006). Expression
of several genes was ampliﬁed using several Taqman assays
(Invitrogen) including p27 (ID: Dr03101119_ml) and β-actin1 (ID:
Dr0332610_m1). Permission for the ink4ab Taqman probe (ID:
AJ1RUB6) was provided graciously by Dr. Hatem Sabaawy.
Cartilage staining of whole mounts
At 4 dpf, zebraﬁsh were anesthetized with tricaine and ﬁxed
with cold 4% paraformaldehyde solution (PFA). Zebraﬁsh cartilage
was stained with Alcian blue and Alzarian Red as previously
described (Walker and Kimmel, 2007). Zebraﬁsh were imaged in
glycerol and bright-ﬁeld images were taken using a Leica MZ10F
ﬂuorescent microscope.
Cartilage sectioning
Zebraﬁsh morphants were anesthetized with tricaine and ﬁxed
with cold 4% PFA at 4 dpf. The sample preparation, sectioning, and
Alcian blue staining of all zebraﬁsh embryos were performed by
Histoserv, Inc. (Germantown, MD). All embryos were sectioned at
10 μm.
Whole-mount antibody labeling
At 25 hpf, zebraﬁsh embryos were anesthetized with tricaine and
ﬁxed with cold 4% PFA overnight at 4 1C. Fixed embryos were rinsed
several times with PBS and permeablilized overnight at room
temperature with 3% Triton in PBS. Embryos were rinsed in PBS
again and blocked in 5% normal goat serum in PBS (blocking
solution) for 3 h at room temperature. Embryos were then incubated
with rabbit anti-phosphorylated Histone H3 (phospho-ser10) anti-
body (1:200, Cell Signal #9701) diluted in blocking solution over-
night at 4 1C. Embryos were rinsed several times over 6 h in blocking
solution and incubated overnight at 4 1C with goat anti-rabbit
AlexaFluor 488 (1:200, Invitrogen A-11008). Embryos were rinsed
in blocking solution for 2 h. Zebraﬁsh were stored in VECTASHIELD
mounting medium (VECTOR Laboratories). Fluorescent images were
taken on a Leica MZ10F microscope after mounting zebraﬁsh in 0.1%
agarose.
Quantiﬁcation of proliferation
Quantiﬁcation of the cellular area expressing ﬂuorescently
labeled P-H3 was performed using Adobe Photoshop as previously
described (Lehr et al., 1999). Mitotic cells were quantiﬁed by
calculating the average ﬂuorescent area (pixel2). Five cells within
each ﬂuorescent image were selected using the Photoshop Magic
Wand Tool. On selection of the ﬁve mitotic cells, cells of similar
ﬂuorescent intensity were selected using the “Select Similar”
command with a stringency factor of 20. Cells were not selected
S.A. Balow et al. / Developmental Biology 382 (2013) 57–6968for based on intensity; however, selected cells in the plane of focus
tended to be slightly higher in ﬂuorescent intensity. The average
pixel area was calculated for each image and the process was
repeated across three separate z-planes for each zebraﬁsh embryo.
The three averaged pixel areas from the z-planes were again
averaged to give a total average pixel area for each individual
embryo. The total average pixel areas from multiple zebraﬁsh
embryos were plotted and statistical signiﬁcance was determined
using a Student's t-test.
To count the number of P-H3-positive cells, zebraﬁsh embryos
were imaged on a Leica SP2 confocal microscope. Z-plane images
were taken throughout the embryo at 40 μm steps to avoid
capturing cells in multiple z-planes. The cells were then manually
counted by an individual who was blind to the identity of the
morpholino used in the experiment, to avoid bias. The data were
then stratiﬁed by the morpholino used (Standard versus chd7), and
the results were plotted and tested for statistical signiﬁcance using
a Student's two-tailed t-test.Acknowledgments
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